-+ 0.00%
-+ 0.00%
-+ 0.00%

Nexalin item-level analysis of Alzheimer’s trial data flags sustained gains in memory and language domains

PUBT·09/03/2026 12:32:24
Listen to the news
Nexalin item-level analysis of Alzheimer’s trial data flags sustained gains in memory and language domains
  • Nexalin released a new post-hoc review of results from its previously published, sham-controlled Alzheimer’s device trial.
  • The analysis pointed to improvements in key cognitive functions, with benefits still seen months after treatment ended.
  • Findings are intended to shape endpoint choices and patient selection for a planned U.S. Alzheimer’s pilot study of its Gen-2 SYNC console.
  • Management framed the results as hypothesis-generating rather than definitive evidence of efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030830PRIMZONEFULLFEED9820543) on September 03, 2026, and is solely responsible for the information contained therein.